Effectiveness and safety of switching biologics after secukinumab treatment failure in moderate-to-severe plaque psoriasis: a retrospective cohort study - Summary - MDSpire
Advertisement
Effectiveness and safety of switching biologics after secukinumab treatment failure in moderate-to-severe plaque psoriasis: a retrospective cohort study
To evaluate the effectiveness and safety of switching to ixekizumab, guselkumab, or ustekinumab in patients with moderate-to-severe plaque psoriasis who failed secukinumab.
Approach:
Study Design: Retrospective cohort study analyzing 59 patients who switched from secukinumab to ixekizumab, guselkumab, or ustekinumab.
Endpoints: Primary endpoints included PASI 75, PASI 90, and PASI 100 response rates at weeks 12, 24, and 52.
Data Handling: Missing data were managed using non-responder imputation (NRI).
Key Findings:
Ixekizumab had a higher PASI 75 response rate at week 12 compared to guselkumab and ustekinumab (66.7% vs. 28.1% vs. 16.7%, P = 0.010).
In the secondary failure subgroup, ixekizumab showed a numerical advantage in PASI 75 response at all time points but did not reach statistical significance.
Adverse event rates were 28.6% for ixekizumab, 12.5% for guselkumab, and 33.3% for ustekinumab, with no significant differences between groups (P = 0.281).
Interpretation:
Limitations:
Small sample size may limit the generalizability of findings.
Limited statistical power for subgroup analyses due to sample size.
